STRAMSEN BIOTECH, INC
 |  |  |  |
|---|---|---|---|
 |  |
SEC STATUS
SEC Filing Status
Since our inception in November 2020, Stramsen Biotech, Inc. has emerged as a pioneering force within the biopharmaceutical industry. Over the past few years, we have made significant advancements in the development of groundbreaking plant-based medicines. These achievements have positioned our firm at the forefront of innovation, consistently raising the standard for modern patient care.
Stramsen Biotech, Inc. is currently poised to raise up to $75,000,000 through our Regulation A offering. To achieve this, we are leveraging a strategic combination of private fundraising options, including Regulation D, Regulation A, and Regulation Crowdfunding (CF). This multi-faceted capital strategy allows us to engage with diverse investor pools while maximizing our potential for long-term growth and scientific innovation.
As we prepare for this transformative next chapter, we are actively seeking partnerships with premier investment banks and law firms to serve as underwriters for our potential IPO. We invite interested parties to contact us promptly to explore this exceptional opportunity to collaborate with a leading force in the biopharmaceutical sector. Our commitment to transparency and growth is further evidenced by our recent regulatory milestones.
We are pleased to announce that we have already taken significant steps toward our offering. On May 20, 2024, we successfully filed Form D under Rule 506(c) with the SEC. This filing serves as a cornerstone of our financial roadmap as we transition toward the public markets. Our structured approach ensures that we remain compliant while pursuing aggressive expansion goals.
As of March 2024, Stramsen Biotech, Inc. maintains a robust equity capital structure designed to support our ambitious global objectives. The company has authorized 750,000,000 shares, with approximately 229,041,217 shares currently outstanding. Based on our most recent valuation of $19,000,000,000, our private market share price stands at approximately $82.95 per share.
This valuation reflects the market's deep confidence in our innovative biotech solutions and our sustained potential for future growth. We invite you to join us in our mission to revolutionize patient care through the power of plant-based medicine. Invest in Stramsen Biotech, Inc., where nature meets innovation and transformation becomes a reality.